Rades Dirk, Doehring Laura, Staackmann Christian, Streubel Maria Karolin, Janssen Stefan, Bartscht Tobias, Bohnet Sabine
Department of Radiation Oncology, University of Lübeck, 23562 Lübeck, Germany.
Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Lübeck Campus, 23538 Lübeck, Germany.
Clin Pract. 2025 Jul 25;15(8):139. doi: 10.3390/clinpract15080139.
BACKGROUND/OBJECTIVES: Most patients with non-small cell lung cancer (NSCLC) receive chemo- and/or immunotherapy, which can be associated with adverse events including fatigue. Affected patients may not be able to receive the complete chemo- and/or immunotherapy as planned. In this context, patients may benefit from maintaining their physical activity, which can be challenging. An app reminding patients to perform a certain number of steps may have a positive effect on physical activity during chemo- and/or immunotherapy. Such an app is under development and will be tested in a prospective trial. The current APACHIE-01 study (NCT06993896) is required for proper sample size calculation and design of the planned trial.
The main goal of the APACHIE-01 study is to evaluate patterns and predictors of physical activity during chemo- and/or immunotherapy for locally advanced or metastatic NSCLC. The primary endpoint is the assessment of the mean number of steps per week during the first three cycles of chemo- and/or immunotherapy for lung cancer. The baseline value is represented by the mean number of steps during the last week prior to chemotherapy and/or immunotherapy. Secondary endpoints include associations between mean number of steps per week and a pain score, a distress score, and a fatigue score. The recruitment of the required 38 patients should be completed within 4 months and the treatment period will be 9-10 weeks (three cycles of chemo- and/or immunotherapy), resulting in a total running time of approximately 6 months. The APACHIE-01 study will contribute to the optimal design of a subsequent prospective trial.
背景/目的:大多数非小细胞肺癌(NSCLC)患者接受化疗和/或免疫治疗,这可能会引发包括疲劳在内的不良事件。受影响的患者可能无法按计划接受完整的化疗和/或免疫治疗。在这种情况下,患者可能会从保持身体活动中受益,但这可能具有挑战性。一款提醒患者完成一定步数的应用程序可能会对化疗和/或免疫治疗期间的身体活动产生积极影响。这样一款应用程序正在开发中,并将在前瞻性试验中进行测试。当前的APACHIE - 01研究(NCT06993896)对于计划试验的适当样本量计算和设计是必要的。
APACHIE - 01研究的主要目标是评估局部晚期或转移性NSCLC患者在化疗和/或免疫治疗期间身体活动的模式和预测因素。主要终点是评估肺癌化疗和/或免疫治疗前三个周期每周的平均步数。基线值由化疗和/或免疫治疗前最后一周的平均步数表示。次要终点包括每周平均步数与疼痛评分、痛苦评分和疲劳评分之间的关联。招募所需的38名患者应在4个月内完成,治疗期为9 - 10周(三个周期的化疗和/或免疫治疗),总运行时间约为6个月。APACHIE - 01研究将有助于后续前瞻性试验的优化设计。